Deuteporfin Tolerance and Pharmacokinetics in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01481597
Recruitment Status : Completed
First Posted : November 29, 2011
Last Update Posted : May 16, 2012
Information provided by (Responsible Party):
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

Brief Summary:
Deuteporfin, a novel photodynamic drug developed in China, displays good photodynamic antitumor activity. The purpose of the present study is to investigate the safety and pharmacokinetics of intravenous deuteporfin in healthy Chinese volunteers following single-dose administration.

Condition or disease Intervention/treatment Phase
Healthy Drug: deuteporfin Drug: placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Tolerance and Pharmacokinetics of Single-dose Intravenous Deuteporfin in Healthy Volunteers
Study Start Date : November 2011
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012

Arm Intervention/treatment
Experimental: deuteporfin 1mg/kg Drug: deuteporfin
deuteporfin 1 mg/kg IV as a single dose

Active Comparator: deuteporfin 2.5mg/kg Drug: deuteporfin
deuteporfin 2.5 mg/kg IV as a single dose

Active Comparator: deuteporfin 5mg/kg Drug: deuteporfin
deuteporfin 5 mg/kg IV as a single dose

Active Comparator: deuteporfin 7.5mg/kg Drug: deuteporfin
deuteporfin 7.5 mg/kg IV as a single dose

Placebo Comparator: placebo Drug: placebo
Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)

Primary Outcome Measures :
  1. number of participants with adverse events [ Time Frame: up to 19 days following injection ]
    number of participants with adverse events as a measure of safety and tolerability of single dose of deuteporfin administered to healthy subjects

Secondary Outcome Measures :
  1. Pharmacokinetic profile [ Time Frame: predose, 20, 40 and 60 min during-dose, and 5, 10, 20, 40 min and 1, 1.5, 2, 3, 4, 6, 8 ,12, 24h post-dose ]
    Pharmacokinetic profile: Cmax (Peak Concentration), AUC (area under the plasma-concentration-time curve ), T1/2 (half life)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Chinese healthy male and/or female subjects
  • 18 to 45 years old with Body mass index (BMI) within the range of 19 to 24 kg/m2
  • weigh at least 45 kg for female subjects or 50 kg for male subjects
  • In good health as confirmed by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis on the screening and baseline evaluation
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

  • Significant illness or major surgery within four weeks prior to dosing
  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies and photoallergy)
  • Use of any drugs which might interfere with drug absorption, distribution, metabolism, excretion or cause photoallergy within 30 days prior to dosing, or any drugs within 14 days prior to dosing
  • Participation in any clinical investigation within 30 days prior to dosing
  • Smokers, alcoholics, drug abusers
  • Immunodeficiency diseases, including a positive HIV test result, Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result
  • pregnancy or lactation for female subjects

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01481597

China, Hunan
Xiangya Hospital of Central-South University
Changsha, Hunan, China, 410008
Sponsors and Collaborators
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Principal Investigator: Zeneng Cheng, Ph.D Xiangya Hospital of Central South University
Study Director: Jining Tao, Master Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Principal Investigator: Pingsheng Xu, Master Xiangya Hospital of Central South University

Responsible Party: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Identifier: NCT01481597     History of Changes
Other Study ID Numbers: FDZJ1109DT
First Posted: November 29, 2011    Key Record Dates
Last Update Posted: May 16, 2012
Last Verified: May 2012

Keywords provided by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.:
healthy volunteers